A Study on the Tolerability of Capecitabine plus Oxaliplatin as Adjuvant Chemotherapy.
|
| Abstract | AIM: Tolerability, adverse events, and long-term outcomes were compared and analyzed between patients receiving oral anticancer agent-based adjuvant chemotherapy regimen (PO group) and those receiving combination adjuvant chemotherapy with oxaliplatin (OX group), after curative resection of colorectal cancer at our Department. PATIENTS AND METHODS: The subjects included in the study were 169 patients with stage III colorectal cancer who underwent curative resection and received postoperative adjuvant chemotherapy between June 2007 and October 2014. Fifty-three patients were included in the OX group, while 116 patients were included in PO group. RESULTS: No significant difference was observed in treatment completion rates. No significant difference in either the overall or relapse-free survival rates was observed between the two groups. CONCLUSION:
Oxaliplatin has been shown to improve therapeutic outcomes after curative resection of colorectal cancer. Even compared to oral anticancer agents, oxaliplatin appears to be equal in tolerability and treatment completion rate.
|
|---|---|
| Authors | Masayoshi Nakanishi, Yoshiaki Kuriu, Yasutoshi Murayama, Tomohiro Arita, Toshiyuki Kosuga, Ryo Morimura, Hirotaka Konishi, Syuhei Komatsu, Atsushi Shiozaki, Hisashi Ikoma, Daisuke Ichikawa, Hitoshi Fujiwara, Kazuma Okamoto, Eigo Otsuji |
| Journal | Anticancer research (Anticancer Res) Vol. 36 Issue 4 Pg. 1851-4 (Apr 2016) ISSN: 1791-7530 [Electronic] Greece |
| PMID | 27069169 (Publication Type: Controlled Clinical Trial, Journal Article) |
| Copyright | Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!